Compare ARK Innovation ETF (ARKK) vs Canopy Growth Corp (CGC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Innovation ETF vs Canopy Growth Corp — how do they compare? ARK Innovation ETF trades at $79.8, while Canopy Growth Corp trades at $0.97 (market cap $407.38M). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| ARKK | CGC | |
|---|---|---|
52-Week High | $92.50 | $1.92 |
52-Week Low | $63.52 | $0.86 |
Market Cap | — | $407.38M |
Sector | — | Health |
Enterprise Value | — | $346.82M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $80.25, down 1.58% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF has gained about 2% year-to-date through late June, sitting near its pivot point of $81. Recent news highlights Cathie Wood's continued stock purchases during pullbacks while the fund faces criticism for its 0.75% expense ratio and underperformance relative to broader tech markets.
The outlook remains mixed with strong technical momentum but fundamental concerns about fees and concentrated exposure to volatile innovation stocks. Key risks include Tesla's 10% weighting creating single-stock vulnerability and the fund's history of 37.88% losses over five years despite recent investor interest resurgence.
Canopy Growth (CGC) trades at $0.97, down 0.28% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses. Cash flow remains negative, but the balance sheet improved with a debt-to-asset ratio of 33.13% in 2025. Analyst sentiment is divided, with 33% buy ratings amid ongoing profitability challenges and potential reverse stock split discussions.
The outlook for CGC hinges on achieving profitability and navigating regulatory hurdles, with projected revenue growth to $285 million in 2026 offering a potential catalyst. Key risks include persistent losses, high debt, and Nasdaq compliance concerns, while institutional interest remains cautious. Investors should weigh the speculative turnaround potential against significant financial and operational headwinds in the volatile cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
